After the Supreme Court’s ruling in Warner-Lambert v Generics, clinicians and pharmacists can breathe a sigh of relief that they will not be personally exposed to patent litigation. But the decision raises some questions for innovative pharmaceutical companies. How does it impact the incentives available for researching new uses for existing medicines? Our patent experts Alasdair Poore and Mark Pearce discuss the issues.
23 Aug 2022
< 1 minute read